



## PRESS RELEASE

# Care Oncology Open for Patient Services with COC Protocol Adjunctive Cancer Treatment

**Care Oncology ready to provide adjunctive cancer treatment in the United States. A four-year clinical study in the UK of the COC Protocol shows statistically significant results in the treatment of Glioblastoma. Similar outcomes possible for adjunctive treatment of other cancers.**

**March 16, 2018 – London, UK** – Care Oncology, a UK-based company, announced today that it is prepared to provide patient services in the United States with its patented COC Protocol, an adjunctive cancer treatment that it has developed.

The COC Protocol underwent a four-year clinical study. The clinic recently released results of the study that showed that the protocol doubled survivability for patients suffering from Glioblastoma, a form of brain cancer. Patients that showed improvement received both the protocol and standard-of-care cancer treatment (chemo, radiotherapies).

According to the company website ([www.careoncology.com](http://www.careoncology.com)), COC Protocol incorporates a combination of well-known medications used for the treatment diabetes, coronary heart disease, and mild infections.

“None of the medications included in the COC Protocol are experimental,” says Jason Butcher, Director of Operations. “Most of them have been in use for more than 20 years and are safe. And that’s the magic – the COC Protocol prescribes well-established drugs against a disease that still defies the best and most complex medicines that have been developed, at a fraction of the cost.”

According to Butcher, COC Protocol is not a “targeted therapy – they call it ‘adjunctive therapy’ because it’s used with standard-of-care therapies like chemo and radiation.”

Paraphrasing additional clinical material from the study, medications used in the COC Protocol target the metabolic and signaling dysfunctions that are common in all cancer cells, regardless of their tissue of origin.

“What that means is that this protocol can be effective against all kinds of cancer when it is used with other standard-of-care therapies,” says Butcher. He points to the company’s website where there is a growing list of studies that support his claim that the same drugs used in the COC Protocol may extend far beyond patients with glioblastoma. “There’s more than ten years of research from universities and medical research all over the world that shows that these medications promote anti-cancer activity across a broad spectrum of cancer types.”

Butcher, who is currently a COC Protocol patient, notes that the study of the Protocol is ongoing. “Our friends in the UK are still taking in patient data. Eventually we will collect patient data here in the U.S.

and add to that study. But if the current medical discussion is any indication, I think that this is already a ground-breaking development in cancer treatment.”

What is unique about Care Oncology is how the treatment is delivered to patients.

In the United States, all clinical interaction is done online with US-based physicians who are trained to administer the protocol. Patients are screened for conditions that may prevent them from safely using the protocol. Once approved for the protocol, direct interaction with Care Oncology physicians is facilitated via an online conferencing system. Often, the medications can be sent to the patient via the mail or picked up from a local pharmacy.

“We’re trying to make this treatment as accessible as possible,” says Butcher. “Patients are already under the care of an oncologist. We provide a little insurance that helps make the standard-of-care treatments more effective.”

Butcher points out that the annual cost of the COC Protocol is less than 1% of the annual cost of most standard-of-care cancer treatment programs. “It’s actually a lot less than 1% for patients who need experimental cancer treatment,” he adds.

For more information, visit [www.careoncology.com](http://www.careoncology.com)

Care Oncology operates in the United States and has a clinic in the UK. The headquarter offices are located at 40 Harley Street, London, W1G 9PP. The US phone number is 800-392-1353.

###